Back to GEODE CAPITAL MANAGEMENT, LLC GEODE CAPITAL MANAGEMENT, LLC

LYELLYEL
5 quarters

Position history for GEODE CAPITAL MANAGEMENT, LLCGEODE CAPITAL MANAGEMENT, LLC's holdings in LYELL IMMUNOPHARMA INC

Yes. Geode Capital Management holds 310,636 shares of LYEL (Lyell Immunopharma), worth $4.4M, as of its Q2 2026 13F filing. It increased the position by 143,656 shares (+86.0%) from Q1 2026. Geode Capital Management has held LYEL in every 13F on record since Q2 2025, 5 quarterly filings.

Current Value

$4.4M

Current Shares

310,636

Total Value Change

+$3.5M

Total Shares Change

+207,366

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
310,636
+86.0%
$4.4M0.0%$14.05
42
2026-Q1
Increased
166,980
+2.4%
$3.4M0.0%$23.33
27
2025-Q4
Increased
162,997
+25.1%
$5M0.0%$31.59
33
2025-Q3
Increased
130,257
+26.1%
$2.1M0.0%$14.97
32
2025-Q2
New
103,270
-
$913,2610.0%$8.94
34

Other major holders of LYEL: VANGUARD GROUP INC, VANGUARD CAPITAL MANAGEMENT LLC, BlackRock, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used